Gabelli Funds LLC cut its stake in shares of Cooper Companies Inc (NYSE:COO) by 16.5% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 50,500 shares of the medical device company’s stock after selling 10,000 shares during the period. Gabelli Funds LLC owned approximately 0.10% of Cooper Companies worth $13,996,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in COO. Janus Henderson Group PLC lifted its position in Cooper Companies by 23.8% during the 2nd quarter. Janus Henderson Group PLC now owns 2,618,690 shares of the medical device company’s stock worth $616,595,000 after acquiring an additional 502,783 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in Cooper Companies by 11.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,054,418 shares of the medical device company’s stock worth $719,163,000 after acquiring an additional 323,559 shares in the last quarter. Findlay Park Partners LLP acquired a new position in Cooper Companies during the 2nd quarter worth approximately $53,519,000. Putnam Investments LLC acquired a new position in Cooper Companies during the 2nd quarter worth approximately $44,647,000. Finally, Frontier Capital Management Co. LLC lifted its position in Cooper Companies by 18.0% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 825,561 shares of the medical device company’s stock worth $194,378,000 after acquiring an additional 126,101 shares in the last quarter. 97.07% of the stock is currently owned by hedge funds and other institutional investors.
Shares of COO opened at $267.80 on Friday. Cooper Companies Inc has a 52-week low of $216.47 and a 52-week high of $280.10. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of 23.53, a price-to-earnings-growth ratio of 2.02 and a beta of 0.75. The company has a current ratio of 2.58, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70.
Cooper Companies (NYSE:COO) last announced its earnings results on Thursday, August 30th. The medical device company reported $3.00 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.07 by ($0.07). Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The business had revenue of $660.00 million during the quarter, compared to analyst estimates of $653.44 million. Sell-side analysts expect that Cooper Companies Inc will post 11.62 earnings per share for the current fiscal year.
Several research firms recently commented on COO. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating in a research report on Monday, October 1st. ValuEngine raised Cooper Companies from a “hold” rating to a “buy” rating in a research report on Thursday, September 27th. Raymond James boosted their price target on Cooper Companies from $270.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, September 21st. Oppenheimer set a $270.00 price target on Cooper Companies and gave the stock a “hold” rating in a research report on Friday, August 31st. Finally, BMO Capital Markets boosted their price target on Cooper Companies from $280.00 to $285.00 and gave the stock an “outperform” rating in a research report on Friday, August 31st. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Cooper Companies presently has an average rating of “Buy” and an average price target of $274.25.
In other Cooper Companies news, VP Randal Golden sold 1,731 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The stock was sold at an average price of $275.86, for a total value of $477,513.66. Following the transaction, the vice president now directly owns 1,154 shares of the company’s stock, valued at approximately $318,342.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert S. Weiss sold 58,543 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $252.82, for a total value of $14,800,841.26. Following the sale, the director now directly owns 157,710 shares in the company, valued at $39,872,242.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,809 shares of company stock worth $20,740,667. 1.60% of the stock is currently owned by corporate insiders.
Cooper Companies Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Further Reading: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.